MLTX News and Press, MoonLake Immunotherapeutics From 02/14/23

Cantor Fitzgerald launched its coverage on MoonLake Immunotherapeutics ( NASDAQ: MLTX ) with an Overweight recommendation on Tuesday, citing $1.5B potential for Sonelokimab, the company's experimental therapy for skin disease Hidradenitis Suppurativa (HS). The analyst Prakhar Agrawal ...

Summary MoonLake is an intriguing investment opportunity in the inflammatory disease space. The company is developing an IL-17 targeting "nanobody". IL-17 is a well-known target in diseases such as psoriatic arthritis. Cosentyx - Novartis' >$3bn per annum revenue drug - also targ...

MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target ...

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody ® sonelokimab in active psoriatic arthritis Phase 2 study represents an important step in psoriatic arthritis clinical development, assessing high threshold outcomes across joint and skin d...

press release ( NASDAQ: MLTX ): Q3 GAAP EPS of -$0.27 beats by $0.07 . As of September 30, 2022, MoonLake held cash, cash equivalents  of $83.5 million, For further details see: GAAP EPS of -$0.27 beats by $0.07

MoonLake Immunotherapeu tics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa (HS) has continued to meet recruitment targets with an expected primary endpoint readout in mid-2023 ...

MoonLake Immunotherapeutics to i nitiate g lobal Phase 2 s tudy of the Nanobody ® s onelokimab in p atients with active psoriatic arthritis MoonLake announces FDA clearance for Phase 2 clinical study of the...

MoonLake Immunotherapeutics ( NASDAQ: MLTX ) on Tuesday said it had signed a services agreement with contract development and manufacturing organization Vetter Pharma International GmbH. As per the deal, Vetter will be responsible for fill and finish services. Vetter w...

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics AG (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focuse...

Gainers: 1Life Healthcare ( ONEM ) +69% . Tabula Rasa HealthCare ( TRHC ) +52% . Vertical Aerospace ( EVTL ) +41% . Moon Lake Immuno therapeutics ( MLTX ) +32% . Altice USA ( ATUS ) +26% . Kaltura ( KLTR ) +22% . ...